Clinical Trials Browser

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 2 Active not recruiting

90 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2 Recruiting

111 enrolled

EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Phase 2 Terminated

6 enrolled 11 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

35 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05361720 2025-07-23

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase 2 Recruiting

54 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07043608 2025-07-02

ZAMBONI

Phase 2 Not yet recruiting

20 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT06783348 2025-01-23

RENALUT

Phase 2 Not yet recruiting

48 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT01693822 2024-11-21

A-PREDICT

Phase 2 Completed

65 enrolled 15 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02978404 2024-06-28

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Phase 2 Completed

26 enrolled

CNSDermatologicGenitourinaryThoracic

Clear-cell metastatic renal cell carcinoma, Brain Neoplasms, Melanoma, Small Cell Lung Carcinoma

NCT05567588 2024-02-01

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

Phase 2 Unknown

66 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT05879471 2023-07-24

68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Unknown

39 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03679767 2023-07-21

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Phase 2 Completed

121 enrolled 25 charts

DermatologicGenitourinaryThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02917772 2022-10-06

TITAN-RCC

Phase 2 Completed

200 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03334409 2022-03-31

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 2 Terminated

5 enrolled 16 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01896271 2021-08-23

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Phase 2 Completed

30 enrolled 12 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms, Neoplasm Metastasis

NCT02960906 2021-04-26

BIONIKK

Phase 2 Completed

200 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT02019576 2021-03-23

Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

Phase 2 Completed

38 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01391130 2019-07-23

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Phase 2 Terminated

110 enrolled 14 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Neoplasm Metastasis, Neoplasms

NCT01499121 2018-03-06

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Phase 2 Completed

117 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT01715935 2016-08-19

NEORAD

Phase 2 Completed

25 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02002312 2015-08-13

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Phase 2 Completed

14 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Clinical Trials

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

ZAMBONI

RENALUT

A-PREDICT

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

TITAN-RCC

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

BIONIKK

Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NEORAD

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer